Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Oxidative Phosphorylation Dysfunction Modifies the Cell Secretome

Garrido-Pérez N., Vela-Sebastián A., López-Gallardo E., Emperador S., Iglesias E., Meade P.

Narrative Review, published in Int J Mol Sci (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Mol Sci (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32397676
PMCID
PMC7246988
DOI
10.3390/ijms21093374
Citations
14

Abstract (original English)

Mitochondrial oxidative phosphorylation disorders are extremely heterogeneous conditions. Their clinical and genetic variability makes the identification of reliable and specific biomarkers very challenging. Until now, only a few studies have focused on the effect of a defective oxidative phosphorylation functioning on the cell's secretome, although it could be a promising approach for the identification and pre-selection of potential circulating biomarkers for mitochondrial diseases. Here, we review the insights obtained from secretome studies with regard to oxidative phosphorylation dysfunction, and the biomarkers that appear, so far, to be promising to identify mitochondrial diseases. We propose two new biomarkers to be taken into account in future diagnostic trials.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMitochondrial DiseasesVascular Endothelial Growth Factor AFibroblast Growth FactorsDNA, MitochondrialInterleukin-6Oxidative PhosphorylationGrowth Differentiation Factor 15Secretory PathwayBiomarkers

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.